

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED

Representative: Joji Nakayama, President and CEO

(Code no.: 4568, First Section, Tokyo Stock Exchange)

Please address inquiries to Noriaki Ishida, Corporate Officer,

Vice President, Corporate Communications Department

Telephone: +81-3-6225-1126

<http://www.daiichisankyo.com/>

### **Daiichi Sankyo Selects Research Partners for TaNeDS Collaborative Drug Discovery Project**

**Tokyo, Japan (October 23, 2013)** — Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has selected research partners for its TaNeDS (**T**ake a **N**ew challenge for **D**rug **d**iscovery) collaborative drug discovery project. The researchers were selected from universities and public research centers in Japan. Daiichi Sankyo will soon begin signing agreements with the selected parties to initiate collaborative research.

1. Total entries: 222

2. Selected parties: 23

3. Selections by entry type

	Entries	Those that passed second selection	Final selections
A. Daiichi Sankyo's Desired Research Themes	215	33	20
B. RD Novare's Desired Research Themes*	7	3	3
Total	222	36	23

4. Selections by research theme

	Entries	Those that passed second selection	Final selection
A. Daiichi Sankyo's Desired Research Themes			
i. Oncology	71	9	5
ii. Cardiovascular metabolics	75	2	2
iii. Leading edge pharmaceuticals	57	4	3
iv. Enhancement of current research projects	44	5	3
v. Antibodies	37	7	2
vi. Nucleic acid therapeutics, peptide pharmaceuticals, DDS	40	3	2
vii. Biomarkers	41	0	0
viii. Drug Safety, ADME(Drug Absorption, Distribution, Metabolism, Excretion)	44	4	3
ix. Pharmaceutical technology platforms	0	0	0

B. RD Novare's Desired Research Themes			
Drug discovery and development technology platform research	7	3	3
Total (Entries with multiple themes are counted once for each theme)	419	36	23

\* Daiichi Sankyo RD Novare Co., Ltd. (hereafter, RD Novare), Daiichi Sankyo's wholly owned subsidiary, joined TaNeDS to promote the development of novel technology platforms for drug discovery, in 2013.

For reference: 2012 TaNeDS project overview (from March 6, 2013 press release)

# 1. Project overview

## 1) How to apply

Project type		Objective	Applicable person/group	Duration	Scope of funding (total)
A. Daiichi Sankyo's Desired Research Themes	Feasibility research	Discovery and development of initial drug discovery themes and new technologies	Researchers in Japan	Completion of contract to March 31, 2015	Up to 10 million yen
	Collaborative research	Discovery and development of initial drug discovery themes and new technologies in collaboration with Daiichi Sankyo	Researchers and research teams in Japan	Completion of contract for one or two years*	Up to 20 million yen (up to 10 million yen per year)
B. RD Novare's Desired Research Themes	Feasibility research	Drug discovery and development technology platforms	Researchers in Japan	Completion of contract to March 31, 2015	Up to 5 million yen

\*Project duration subject to change based on research

Target project numbers: 18 for A, and 2 for B

A. Desired research themes by Daiichi Sankyo: 1) Exploratory research themes and research themes that will lead to initial drug discovery in the idea stage; 2) research themes that will lead to practical application of intellectual properties and proprietary know-how; and 3) technologies being researched academically that are applicable to solving challenges faced in terms of pharmaceutical manufacturing process development and quality assurance will be accepted. Daiichi Sankyo will determine if feasibility studies with Daiichi Sankyo researchers (preliminary collaborative research) or collaborative research should be conducted based on proposed themes. Accepted themes will be selected

for continuation based on results after the research period comes to a close.

- B. Desired research themes by RD Novare:** Research themes that will lead to the development of the novel technology platforms related to drug discovery will be accepted. Scientists at RD Novare work together on technological seeds being researched academically by applicants to establish leading edge technology platforms and biological evaluation methods.

2) Desired research themes

- Desired research themes by Daiichi Sankyo
  - i. Oncology
  - ii. Cardiovascular metabolics (metabolic disease, heart disease and vascular disease)
  - iii. Leading edge pharmaceuticals
  - iv. Enhancement of current research projects
  - v. Antibodies
  - vi. Nucleic acid therapeutics, peptide pharmaceuticals, DDS
  - vii. Biomarkers
  - viii. Drug Safety, ADME (Drug Absorption, Distribution, Metabolism, Excretion)
  - ix. Pharmaceutical technology platforms
- Desired research themes by RD Novare
  - i. Drug discovery and development technology platform research

\* For more information about the TaNeDS program visit the Daiichi Sankyo corporate website: <http://www.daiichisankyo.co.jp/corporate/rd/taneds/>

3) Who is eligible

Researchers from universities and public research centers who can conduct research in Japan

4) Schedule

Application period:	May 20 to June 14, 2013
First selection period:	June 17 to July 31, 2013
Second selection period:	August 1 to September 30, 2013
Contract negotiation:	From October 1, 2013
Start of research:	Upon completion of contract

\*For more information about the TaNeDS program visit the Daiichi Sankyo corporate website: <http://www.daiichisankyo.co.jp/rd/taneds/index.html> (Japanese only)